Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:2/4/2008

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will present at the 10th Annual BIO CEO & Investor Conference 2008 on Monday, February 11, at 11:45 a.m. Eastern Time at the Waldorf-Astoria in New York.

Dr. McMahon will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile compared to currently available platinum-based therapies. Picoplatin is designed to overcome and prevent platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, combinations and formulations. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and hormone-refractory prostate cancers. For additional information please visit http://www.poniard.com.

(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved. Poniard and Poni
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Locally owned, Greek olive oil producer and ... week as having one the best Extra Virgin Olive Oils ... Peloponnese region of Greece and known as Laconiko , ... of Medium Olive Oil, which is defined by the competition ... over 700 producer applicants from 25 different countries applying, Laconiko ...
(Date:5/6/2015)... DC (PRWEB) May 06, 2015 ... organization representing the regenerative medicine and advanced therapies ... quarterly data report, offering an in-depth look at ... through March 2015. , The report is available ... graphics highlighting key data points, available here ...
(Date:5/6/2015)... Water NSW (New South Wales) in ... distribute imagery, LiDAR, and Elevation Data within the organisation. ... on earth, and the need to ensure a reliable ... rainfalls has driven the development of several complex and ... water supplies for NSW, including high quality drinking water ...
(Date:5/6/2015)... 2015 TransferSoft® Inc. today ... VC funding and launched its HyperTransfer™ data movement ... software enables applications to more reliably, efficiently, and cost ... systems and locations. Available now for integration into OEM ... line speed, independent of file size or depth of ...
(Date:5/6/2015)... 06, 2015 The GUARDaHEART Foundation was ... Resource Exchange with the mission of providing basic living ... in need on Thursday, April 30th. , Through ... blood test for the early-detection and diagnosis of heart ... advanced medical testing to homeless individuals and families. ...
Breaking Medicine News(10 mins):Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 2Health News:Water NSW Unlocks Imagery and Elevation Data Archive Across the Enterprise using Hexagon Geospatial Solutions 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 2Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 3Health News:TransferSoft Launches Industry’s Most Comprehensive Data Movement Technology Suite to Optimize Disaster Recovery, Big Data, and Cloud Applications 4Health News:GUARDaHEART and Starbucks® Collaborate for Impactful Event to Help Homeless Families 2
... Cystic Fibrosis -, DUCK KEY, Fla., April 15 ... hosted by Hawks Cay on Duck,Key in the Florida Keys ... Wade Boggs, a member of the National Baseball Hall ... Boggs is a former third baseman in,Major League Baseball, primarily ...
... -- A new study by researchers at the University ... gender-related differences in the development and survival of metastatic ... published in the April 15 issue of the journal ... the development of colon cancer resulted in opposite survival ...
... Film ... Technology -, WARREN, N.J., April ... film pharmaceutical products,today announced that it has been granted U.S. patent No. ... is,expected to issue on April 15, 2008, relates to the Company,s proprietary,mixing ...
... actress, Cynthia Nixon,best known for her role as Miranda ... Susan G. Komen for the Cure, the world,s largest,breast ... her,personal experience with breast cancer, attend key events and ... Service Announcements,designed to educate people about the deadly disease ...
... Archiving Vendor Recognized among Industry Elite ... for its Commitment to the Channel, ... provider of online backup and archiving services, today announced,it is ... 2008,Partner Program Guide (PPG). Inclusion in this guide recognizes the,strength ...
... cancer drug Sutent may slow liver cancer progression, scientists ... A new drug duo might help prevent colorectal cancer, ... the progression of liver cancer. , So conclude two ... Research annual meeting in San Diego. , In the ...
Cached Medicine News:Health News:Hawks Cay Hosts Redbone Sunrise/Sunset Tarpon Tournament 2Health News:USC study finds evidence of gender-related differences in development of colon cancer 2Health News:MonoSol Rx Granted US Patent for Thin Film Manufacturing Process 2Health News:Cynthia Nixon to Serve as Ambassador for Susan G. Komen for the Cure(R) 2Health News:Intronis Technologies eSureIT Partner Program Certified Gold By CMP Channel's VARBusiness 2Health News:Intronis Technologies eSureIT Partner Program Certified Gold By CMP Channel's VARBusiness 3Health News:New Drug Duo Helps Cut Colon Cancer Risk 2Health News:New Drug Duo Helps Cut Colon Cancer Risk 3Health News:New Drug Duo Helps Cut Colon Cancer Risk 4
(Date:5/6/2015)... --  Sigma-Aldrich Corporation (NASDAQ: SIAL ) a leading ... $50,000 product donation to the Reproducibility Project: Cancer ... from recent high-impact papers in the field of cancer ... research marketplace Science Exchange , the non-profit ... eLife. The goal of the project is ...
(Date:5/6/2015)... 2015 First programme ... and rilpivirine   ViiV Healthcare ... clinical trial programme to evaluate the safety and ... ) as maintenance therapy for adult patients with ... studies evaluating 48 week viral suppression with a ...
(Date:5/5/2015)... BARCELONA, Spain , May 6, 2015 ... and aspires to lead the European market in the ... Through this alliance ECUPHAR acquires all the assets ... the new organization in the coming weeks. Being both ... not been disclosed.      (Photo: http://photos.prnewswire.com/prnh/20150506/743274 ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 2ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 3ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 4ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 5ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 6ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 7ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 8ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 9ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy 10ECUPHAR Enters the Spanish and Southern European Markets Through ESTEVE 2
... of its ongoing,efforts to develop research tools that ... disease, The Michael J. Fox,Foundation announced the launch ... the Foundation seeks to drive the creation,and testing ... with a personal,computer and an Internet connection to ...
... March 19 FluoroPharma Inc., a company,developing breakthrough ... (PET) market, announced commencement of Phase,I clinical trials ... the proposed studies. The Phase I trial is ... safety, distribution and dosimetry,of BFPET as a PET ...
Cached Medicine Technology:New Michael J. Fox Foundation Initiative Will Drive Development of Web-Based Tools to Increase Patient Participation in Parkinson's Clinical Trials 2FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2
All-natural porcine collagen can be used in open or laparoscopic placement....
... SBI RingFix is a modular external fixation ... large variety of clinical needs. Originally marketed ... has a successful 20 year history of ... Developed around the principles of the Ilizarov ...
... The six models of Thermo Scientific ... mL to 60 mL with very high ... careful design of all components. The Finnpipette ... the extensive Thermo Scientific Finnpipette manual liquid ...
... collection benefits from innovative research in materials ... such as the aerospace and automotive industry, ... and the footwear and textile industry. , ... in the Carrera sunglasses collection to create ...
Medicine Products: